{
    "clinical_study": {
        "@rank": "16583", 
        "arm_group": {
            "arm_group_label": "Active anodal HD-tDCS", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will undergo 20 minutes active HD-tDCS."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the mean number of stimulation (high\n      definition-transcranial direct current stimulation) sessions (up to 26) needed to achieve a\n      clinical response with this response defined as a 50% decrease in Visual Analog Scale (VAS)\n      for pain. These data will be important in defining the optimal number of sessions for future\n      fibromyalgia subjects in Phase III trials."
        }, 
        "brief_title": "Single-arm, Open-label, Phase II Trial of HD-tDCS in Fibromyalgia Patients", 
        "condition": [
            "Fibromyalgia", 
            "Chronic Pain"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fibromyalgia", 
                "Myofascial Pain Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Providing informed consent to participate in the study\n\n          -  18 to 85 years old, both male and female\n\n          -  Have a diagnosis of Fibromyalgia\n\n          -  Existing pain for more than 3 months with an average of at least 4 on a 0-10 VAS\n             scale\n\n          -  Pain resistant to common analgesics and medications for chronic pain such as Tylenol,\n             Aspirin, Ibuprofen, Soma, Parafon Forte DCS, Zanaflex and Codeine.\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Contraindications to tDCS: metal in the head or implanted brain medical devices\n\n          -  History of alcohol or drug abuse within the past 6 months as self-reported\n\n          -  Use of carbamazepine within the past 6 months as self-reported\n\n          -  Severe depression (with a  score of >30 in the Beck Depression Inventory)\n\n          -  Any history of epilepsy, stroke, moderate-to-severe traumatic brain injury or severe\n             migraines\n\n          -  History of unexplained fainting spells as self-reported\n\n          -  Neurosurgery as self-reported"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842009", 
            "org_study_id": "2013P000384"
        }, 
        "intervention": {
            "arm_group_label": "Active anodal HD-tDCS", 
            "intervention_name": "High Definition transcranial Direct Current Stimulation", 
            "intervention_type": "Device", 
            "other_name": "4X1 low-intensity direct current stimulator"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "transcranial stimulation", 
            "direct current"
        ], 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Charlestown", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02129"
                }, 
                "name": "Spaulding Rehabilitation Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Single-arm, Open-label, Phase II Trial of HD-tDCS in Fibromyalgia Patients", 
        "overall_contact": {
            "email": "ffregni@partners.org", 
            "last_name": "Felipe Fregni, MD PhD MPH", 
            "phone": "617-952-6156"
        }, 
        "overall_contact_backup": {
            "email": "kmweaver@partners.org", 
            "last_name": "Kayleen Weaver, BA", 
            "phone": "617-952-6151"
        }, 
        "overall_official": {
            "affiliation": "Spaulding Rehabilitation Hospital", 
            "last_name": "Felipe Fregni, MD PhD MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Investigate the mean number of sessions (up to 26) needed to achieve clinical response associated with the use of HD-tDCS over the primary motor cortex (M1), with response defined at a 50% decrease in baseline Visual Analogue Scale (VAS) for pain.", 
            "measure": "Mean number of sessions needed to achieve 50% decrease in Visual Analogue Scale (VAS)", 
            "safety_issue": "No", 
            "time_frame": "approximately 4.5 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842009"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Spaulding Rehabilitation Hospital", 
            "investigator_full_name": "Felipe Fregni", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "We will count the number of subjects who achieve clinical response (as defined in Aim 1 as a 50% reduction in baseline VAS) for the duration of the trial.", 
                "measure": "Number of subjects who achieve clinical response", 
                "safety_issue": "No", 
                "time_frame": "Approximately 4.5 months"
            }, 
            {
                "description": "We will measure brain pain response using electroencephalography (EEG) to measure somatosensory Event Related Potentials (ERPs) with a heat pain threshold device. We will also measure auditory ERPs. We will investigate the relationship between these ERP measurements and overall clinical response of patients (as outlined in Aim 1 and Aim 2)", 
                "measure": "Measurement of sensory and auditory evoked potentials", 
                "safety_issue": "No", 
                "time_frame": "Approximately 4.5 months"
            }
        ], 
        "source": "Spaulding Rehabilitation Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "ElMindA Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Spaulding Rehabilitation Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}